Biosign Announces Results of Shareholders Meeting

TORONTO, May 6, 2015 /CNW/ - Biosign Technologies Inc. (TSXV: BIO) ("Biosign" or the "Company") announces that it held an annual and special meeting of shareholders on May 5, 2015 where all of the items of business of the Company were approved, including:

• to re-elect the board of directors, consisting of Dr. Michael Gross, Dennis Rygwalski, Brian Neill and Ron Kelusky,
• to appoint Collins Barrow Toronto LLP, Chartered Accountants as auditor of the Company until the next annual meeting of shareholders or until a successor is appointed at a remuneration to be approved by the board of directors of the Corporation,
• to re-approve the Company's rolling 10% stock option plan,
• to authorize the Company to make an application to be continued under the Canada Business Corporations Act,
• to change the province of the registered office of the Corporation from Ontario to Nova Scotia, and
• to authorize an amendment to the articles of the corporation to consolidate the outstanding common shares of the corporation on an up to one (1) new common share for ten (10) old common shares basis, with the directors being authorized to determine the final consolidation basis within such range.

About Biosign Technologies Inc (TSXV: BIO) Biosign is a developer of world class healthcare software solutions targeted at the Home Care and Allied Health Care markets. The Company's various software divisions, including ClinicServer™, EESI Corporate Benefits and AioMed GmbH offer industry-leading Home Healthcare and Allied Health clinic management solutions to international companies and service providers worldwide.

Forward-Looking Statements

This release contains forward-looking statements. Forward-looking statements, without limitation, may contain the words believes, expects, anticipates, estimates, intends, plans, or similar expressions. Forward-looking statements are not guarantees of future performance. They involve risks, uncertainties and assumptions and Biosign's actual results could differ materially from those anticipated. Forward looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. In the context of any forward-looking information please refer to risk factors detailed in, as well as other information contained in the company's filings with Canadian securities regulators (www.sedar.com).

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE Biosign Technologies Inc.

Biosign Contact Information: Michael Gross, Acting CEO and Chairman, Biosign Technologies, Phone: [phone] ext. 201, Email: [email protected]